Swiss drugmaker Novartis has been on a med tech roll this past year, forging ahead with multiple projects to gain ground in the industry. And at least one of those initiatives, a "smart" contact lens that it's developing with tech titan Google, is already starting to bear fruit.
The first generic version of Novartis' transdermal patch for Alzheimer's has been launched with hopes of getting a slice of the branded med's approximately $400 million in annual sales. Until now Novartis's Exelon Patch was the only transdermal product for the disease on the market.
Novartis scored EU approval for its multiple myeloma med Farydak (panobinostat), months after the FDA signed off on the drug for patients with serious forms of the disease.
Google is keeping up the pace of its push into diabetes. Having got the ball rolling by allying with Novartis in 2014, Google has now added Sanofi to its burgeoning list of diabetes collaborators.
Novartis won't have to wait for European regulators to do a full-force data sift before its new heart failure drug becomes available in England. The U.K. will allow Novartis to roll out its Entresto drug under an early-access scheme begun last year.
The age of biosimilars in the U.S. has finally dawned with the launch of Novartis' Zarxio, a copy of Amgen's Neupogen (filgrastim). And it's arriving with a 15% discount to win scripts over from the brand.
Five years after the University of Pennsylvania began recruiting a small group of 14 patients with hard-to-treat chronic lymphocytic leukemia, researchers are still tracking three of them who are still alive with no signs of their cancer returning after being treated with a first-generation CAR-T therapy.
The French government recently said "oui" to Roche's ($RHHBY) cancer drug Avastin as a cheap, off-label treatment for the blinding eye disease wet age-related macular degeneration (AMD), prompting a resounding "non" from the pharma industry, which is none-too-pleased with the country's latest move.
Amgen is buying into Novartis' early-stage BACE program for Alzheimer's, paying an unspecified upfront and milestones in exchange for a cut of the program, which looks to slash the production of a key toxic protein widely viewed as a prime suspect in the development of the memory-wasting ailment.
Novartis' melanoma duo Tafinlar and Mekinist scored a priority stateside review in July along with a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use. Now the EU has given its final signoff on the combo for patients with a deadly form of the disease.